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Abstract
Rare variants may help to explain some of the missing heritability of complex diseases. Technological advances in
next-generation sequencing give us the opportunity to test this hypothesis. We propose two new methods (one
for case-control studies and one for family-based studies) that combine aggregated rare variants and common
variants located within a region through principal components analysis and allow for covariate adjustment. We
analyzed 200 replicates consisting of 209 case subjects and 488 control subjects and compared the results to
weight-based and step-up aggregation methods. The principal components and collapsing method showed an
association between the gene FLT1 and the quantitative trait Q1 (P<10
−30) in a fraction of the computation time of
the other methods. The proposed family-based test has inconclusive results. The two methods provide a fast way
to analyze simultaneously rare and common variants at the gene level while adjusting for covariates. However,
further evaluation of the statistical efficiency of this approach is warranted.
Background
With recent technological developments in human gen-
ome sequencing, enormous numbers of rare single nucleo-
tide variants can now be detected. This ability to measure
rare variants allows researchers to investigate the multiple
rare variant/common disease model, which may help to
elucidate part of the missing heritability in studies of more
common variants. However, the low frequency of these
rare variants raises issues about how best to analyze them
[1]. In particular, the naive approach, which consists of
testing each variant independently, has little power unless
the sample sizes are large [2]. Instead, one can try to
increase the statistical power by aggregating rare variants
into meaningful groups (e.g., defined by genes, pathways,
or functionality). Several approaches to combining rare
variants have been proposed [2-9], but few address the
issue of combining rare variants with common variants.
The combined multivariate and collapsing (CMC) method
consists of combining the test statistic of the collapsed
rare variants with the univariate tests statistics of the com-
mon variants [3,6]. However, in practice one will often
want to adjust for other covariates. When the number of
common variants within a region is large, the logistic
regression model may be unstable and may not fit well.
To overcome this problem, in this paper we propose two
approaches, one for unrelated case and control subjects
and one for families. The approaches aggregate rare and
common variants into a single variable using a principal
components analysis (PCA). These approaches are applied
to case-control and nuclear family data sets from the
simulations of Genetic Analysis Workshop 17 (GAW17)
[10]. Using the case-control data sets, we also compare
our method to a weight-based collapsing method adapted
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approach [5].
Methods
Principal components and collapsing method
To test jointly the effect of rare and common variants with
a case-control sample, we adapted the CMC method
(described by Dering et al. [3] and Li and Leal [6]) by per-
forming, within each gene, a PCA using one term for the
aggregated score for rare variants and another term for
each of the common variants. We call this the principal
components and collapsing (PCC) method. The first prin-
cipal component is then used in a linear regression model
with other covariates. Combining the collapsed rare var-
iants term and the common variants term into a single
term often gives a more stable fit than the CMC approach.
Collapsing the rare variants before the PCA allows rare
variants to contribute some weight to the PCA and uses
fewer degrees of freedom than the standard multimarker
test collapsing such terms.
A similar method can also be used with a family-based
sampling. Let i index the families, j the offspring, c the
common markers, and r t h er a r em a r k e r s ,a n dl e t
krc =∪.L e tXijc and Xijr be the additive coding for
common and rare genetic variants, respectively. For
each gene, a PCA of all Xijc and of the sum over r of all
Xijr is undertaken. Then, the numerator of our test sta-
tistic is given by:
ST C E C P P ij ij ij ij ijK
k
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⎣
⎤
⎦ ( ) ∑ 1,..., , (1)
where Tij is the mean centered trait or residual from a
regression analysis to adjust for covariates, Cij denotes
the first principal component, and Pijk indicates the cor-
responding parental genotypes. This numerator can be
d e r i v e da sas c o r et e s tf r o mac o n d i t i o n a ll i k e l i h o o d( a s
in [11] or [12]) and would be the standard family-based
association test (FBAT) [13] if Cij was a single variant
rather than the aggregated genetic score. To compute
EC P P ij ij ijK 1...., ⎡
⎣
⎤
⎦ , we use Mendelian transmissions
from the parental mating type, not population allele fre-
quencies. Thus the test is robust to population substruc-
ture. An algorithm for computing EC P P ij ij ijK 1...., ⎡
⎣
⎤
⎦ is
given by Rabinowitz and Laird [14], along with an
extension to more complicated family structures by con-
ditioning on the sufficient statistic for parental genotype
instead of the parental genotype (e.g., when parents are
missing). The test can be thought of as a generalized
covariance between the trait adjusted on covariates and
the collapsed genetic score. The empirical variance of S
is given by:
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Then the test statistic S/[var(S)]
1/2 has a normal
distribution.
Weight-based collapsing
Another way to collapse variants is to weight them by
allele frequency [3], a more appropriate model if less
common variants are increasingly deleterious. To adjust
for covariates, the phenotype is regressed on the nonge-
netic covariates, and then the residuals are used with
the weight-based collapsing (WBC) method [9]. Briefly,
the method weights by the inverse square root of the
variance of the minor allele frequency (MAF) and then
corrects by permutation.
Step-up method
We also applied a separate data-driven collapsing method
(the step-up [SUP] method) proposed by Hoffmann et al.
[5]. Briefly, the approach uses a stepwise routine to deter-
mine the optimal grouping of rare and common variants.
The initial step entails selecting among all variants of a
group (in our case, a gene), the variant k1
* with the stron-
gest univariate test statistic (i.e., lowest P-value). Then all
combinations of all other variants with k1
* are tested
jointly, and the combination kk 12
**   with the lowest
P-value is selected as the best combination if its P-value
is lower than the P-value of the test of k1
* alone. The
algorithm continues until all variants are included in the
model or until all combinations of a rank r have a P-
value higher than that of the previous rank (r − 1).
The PCC method is asymptotic, so no permutation is
necessary to compute the P-value. For the WBC and SUP
methods, we used an adaptive permutation procedure to
compute the P-value (as coded by Hoffmann et al. [5]).
We allowed the tests to have a maximum of 10,000 itera-
tions, after which the P-value was said to be less than
0.0001 if no larger test statistics were observed.
Association at the gene-level was tested using the
three methods on the 200 replicates of 209 case subjects
and 488 control subjects and using the family-based
PCC method on the 200 replicates of 194 nuclear
families derived from the 8 extended families. In the
case-control designs, we adjusted for age, sex, smoking,
and ethnicity using the corresponding variable provided
in the simulations (European, Denver Chinese, Han Chi-
nese, Japanese, Luhya, Tuscan, and Yoruba). All analyses
were undertaken using nonsynonymous variants only.
Variants with a MAF below 5% were considered rare. In
the results, we report the distributions of the P-values
obtained for the top 30 genes ranked by median
Kazma et al. BMC Proceedings 2011, 5(Suppl 9):S29
http://www.biomedcentral.com/1753-6561/5/S9/S29
Page 2 of 7P-value. All analyses were performed without knowledge
of the true simulated model.
Results
Genetic variants
Of the 24,487 variants detected through sequencing of
the mini-exome, 21,355 (87%) had a MAF less than 5%
and 18,131 (74%) had a MAF less than 1%. A total of
9,433 variants (39%) had a variant allele observed only
once among the 697 genotypes (i.e., private alleles seen
in only one individual). The proportion of nonsynon-
ymous variants significantly increased when MAF
decreased: 46.8% of variants with MAF greater than
5%, 50.5% of variants with MAF between 1% and 5%,
and 60.2% of variants with MAF less than 1% (P =4×
10
−56).
Case-control design
Using the PCC case-control method, we found an associa-
tion of the principal component of gene FLT1 with the
quantitative trait Q1 (median P<10
−30)( F i g u r e1 a )a n d
with the dichotomous disease phenotype (median P~10
−4)
(Figure 2a). However, when adjusting for Q1, the associa-
tion with the dichotomous phenotype completely disap-
peared (Figure 2b). We also looked at the association with
Q1 conditioning on the signal of FLT1 and found that all
the median P-values are reduced except for the gene KDR,
which maintains a median P-value close to 10
−4 (Figure
1b). The first principal component explained on average
about 60% of the genetic variability (Figure 3).
The WBC and SUP methods lead to similar conclu-
sions (Figure 4). FLT1 is the gene with the highest med-
ian P-value (>10
−6)a n di st h eo n l yg e n et h a ti s
statistically significant when a stringent Bonferroni cor-
rection for multiple testing is applied. In the top 30 list of
genes discovered by the three methods using the case-
control data sets, 13 genes are common to the three
methods, 4 are common to the PCC and WBC methods,
and 3 are common to the PCC and SUP methods. More-
over, the WBC and SUP methods have 10 genes in com-
mon that do not appear in the top 30 list of the PCC
method. The PCC, WBC, and SUP methods ranked in
their top 30 lists two, four, and five genes, respectively of
t h ee i g h tg e n e st h a th a dat r u ee f f e c to nQ 1 .T a b l e1
reports the average P-values over the 200 replicates
obtained by the three methods for the nine genes with an
effect on Q1.
We compared the run times of the three approaches
used on the case-control data sets. Testing the associa-
tion of phenotype Q1 with all genes on chromosome 1
(where no markers were significant) took 4 s with the
PCC method, 4 s with the WBC method, and 63 s with
the SUP method, whereas on chromosome 13 (where
FLT1 had a P-value less than 0.0001), the PCC method
took 1 s, the WBC method took 170 s, and the SUP
method took 6,079 s.
Family-based design
Using the family-based PCC method, none of the top 30
genes had a median P-value less than 10
−3 (Figure 5).
a b
Figure 1 Top 30 genes associated with Q1 using the principal components and collapsing method with a case-control design.( a )
Association with Q1 adjusting for age, sex, population, and smoking. (b) Association with Q1 adjusting for age, sex, population, smoking, and
FLT1. Box plots represent the distribution of the 200 P-values of the 200 replicates for the 30 genes with the highest median P-values.
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Figure 2 Top 30 genes associated with disease phenotype using the principal components and collapsing method with a case-control
design. (a) Association with disease adjusting for age, sex, population, and smoking. (b) Association with disease adjusting for age, sex, population,
smoking, and Q1. Box plots represent the distribution of the 200 P-values of the 200 replicates for the 30 genes with the highest median P-values.
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Figure 3 Proportion of variability within genes explained by each of the first 10 principal components.
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Page 4 of 7VEGFA and FLT1 ranked first and second with median
P-values of 10
−2 and 10
−3, respectively.
Discussion
The case-control and family-based PCC methods provide
a computationally fast method of simultaneously testing
rare and common variants and adjusting for covariates.
Using a case-control design, the results obtained with the
GAW17 simulations were similar to the results obtained
using the WBC and SUP methods. The PCC methods are
also much faster than the other two permutation-based
approaches. Comparing our results to the true model used
for simulating the data, we found that genes FLT1 and
KDR are indeed part of the gene list that controls the
quantitative trait Q1. These genes have a common variant
(MAF equal to 0.07 and 0.16, respectively) with a moder-
ate or small effect (odds ratio of 1.92 and 1.15, respec-
tively) and nine rare variants, each with an odds ratios
ranging from 1.17 to 2.9. Some of the other genes control-
ling Q1 are represented in the top 30 lists obtained with
the three methods, but none reaches significance when
correction for multiple testing is implemented.
Although the top two genes (VEGFA and FLT1)
obtained with the family-based association test using the
PCC method are in the list of genes controlling Q1, their
test statistics are not significant. This can be explained by
the simulation procedures used for the GAW17 family
data sets, which consisted of eight extended families. Our
analysis split the eight pedigrees into 194 nuclear families
and assumed that the nuclear families were independent.
a b
Figure 4 Top 30 genes associated with Q1 using the weight-based and step-up methods with a case-control design. (a) Weight-based
method adjusting for age, sex, population, and smoking. (b) Step-up method adjusting for age, sex, population, and smoking. Box plots
represent the distribution of the 200 P-values of the 200 replicates for the 30 genes with the highest median P-values.
Table 1 Average P-values obtained with the three methods for the nine genes containing variants with an effect on
phenotype Q1 over 200 replicates
Gene Number of variants Principal components and collapsing method Weight-based collapsing method Step-up method
Total With effect
ARNT 18 5 0.044 0.066 0.041
ELAVL4 10 2 0.177 0.303 0.388
FLT1 35 11 4 × 10
−21 <10
−5 <10
−5
FLT4 10 2 0.132 0.182 0.186
HIF1A 8 4 0.008 0.091 0.074
HIF3A 21 3 0.51 0.488 0.320
KDR 16 11 0.003 0.587 0.059
VEGFA 6 1 0.289 0.2345 0.262
VEGFC 1 1 0.054 0.067 0.080
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a reasonable choice where adjustment on multiple cov-
ariates was needed. However, the first principal compo-
nent accounted on average for 60% of the variability
within the genes. In practice, one might choose to
i n c l u d ee v e nm o r ep r i n c i p al components to capture
more genetic variability. The impact of this on power
would be interesting to evaluate in future studies.
A strength of the PCC approach is its ability to evaluate
large numbers of variants that are not amenable to fitting
with a conventional logistic regression model. Another
solution to this issue is to use shrinkage and variable
selection methods, such as the least absolute shrinkage
and selection operator (LASSO) [15]. Future work could
compare the PCC method to these approaches.
In the PCA of each gene, the number of variables
included was small (less than five in most cases) because
rare variants were aggregated beforehand and only non-
synonymous variants were considered. However, for a
larger number of variables, sparse PCA may provide a
better alternative [16].
Conclusions
In this paper, we propose a new method to analyze all
variants within a predefined region based on the PCA of
the collapsed rare variants term and all common variant
terms. Applying this method to the simulated data sets
of GAW17 provided results similar to two other meth-
ods with a greatly reduced computational time. How-
ever, evaluation of the statistical efficiency of these
approaches is needed on a larger range of models and
different family structures.
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